Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor

Cheolmin Yun, Jae Ryung Oh, Soon Young Hwang, Seong-Woo Kim, Kuhl Huh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To investigate the risk factors for subconjunctival hemorrhage (SCH) after intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) and evaluate the relationship between hemodynamic status at the time of injection and SCH. Methods: We retrospectively reviewed the medical records of 598 cases of 173 patients who underwent intravitreal injection of ranibizumab whose hemodynamic status was monitored at the time of the injection. Cases with SCH after the injection were included in the SCH group. We compared systemic factors, including the hemodynamic status between the SCH group and the control group. Results: The SCH group included 67 cases and the control group included 531 cases without SCH. Baseline hemodynamic status was not significantly related to development of SCH. However, systolic blood pressure (BP) at injection was a significant risk factors for SCH (P = 0.034). Elevated systolic BP, mean arterial pressure (MAP), and pulse rate from baseline to time of injection were significantly related to the development of SCH (P = 0.011, P = 0.014, P = 0.036, respectively). In multivariate analysis, hypertension, a large change in MAP, and a fewer previous injections were significant risk factors for SCH after intravitreal injection (P = 0.030, P = 0.032, P = 0.028, respectively). Conclusions: Hemodynamic risk factors exist for SCH after intravitreal injection of anti-VEGF. To reduce the risk of SCH, strategies should seek to decrease patient anxiety, especially in those with hypertension.

Original languageEnglish
Pages (from-to)1465-1470
Number of pages6
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume253
Issue number9
DOIs
Publication statusPublished - 2015 Sep 26

Fingerprint

Intravitreal Injections
Vascular Endothelial Growth Factor A
Hemorrhage
Hemodynamics
Injections
Blood Pressure
Arterial Pressure
Hypertension
Control Groups
Medical Records

Keywords

  • Anti-vascular endothelial growth factor
  • hemodynamic risk factors
  • Intravitreal injection
  • Subconjunctival hemorrhage

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{365d44edb110489da0ca1cd59f088fce,
title = "Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor",
abstract = "Purpose: To investigate the risk factors for subconjunctival hemorrhage (SCH) after intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) and evaluate the relationship between hemodynamic status at the time of injection and SCH. Methods: We retrospectively reviewed the medical records of 598 cases of 173 patients who underwent intravitreal injection of ranibizumab whose hemodynamic status was monitored at the time of the injection. Cases with SCH after the injection were included in the SCH group. We compared systemic factors, including the hemodynamic status between the SCH group and the control group. Results: The SCH group included 67 cases and the control group included 531 cases without SCH. Baseline hemodynamic status was not significantly related to development of SCH. However, systolic blood pressure (BP) at injection was a significant risk factors for SCH (P = 0.034). Elevated systolic BP, mean arterial pressure (MAP), and pulse rate from baseline to time of injection were significantly related to the development of SCH (P = 0.011, P = 0.014, P = 0.036, respectively). In multivariate analysis, hypertension, a large change in MAP, and a fewer previous injections were significant risk factors for SCH after intravitreal injection (P = 0.030, P = 0.032, P = 0.028, respectively). Conclusions: Hemodynamic risk factors exist for SCH after intravitreal injection of anti-VEGF. To reduce the risk of SCH, strategies should seek to decrease patient anxiety, especially in those with hypertension.",
keywords = "Anti-vascular endothelial growth factor, hemodynamic risk factors, Intravitreal injection, Subconjunctival hemorrhage",
author = "Cheolmin Yun and Oh, {Jae Ryung} and Hwang, {Soon Young} and Seong-Woo Kim and Kuhl Huh",
year = "2015",
month = "9",
day = "26",
doi = "10.1007/s00417-014-2837-6",
language = "English",
volume = "253",
pages = "1465--1470",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor

AU - Yun, Cheolmin

AU - Oh, Jae Ryung

AU - Hwang, Soon Young

AU - Kim, Seong-Woo

AU - Huh, Kuhl

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Purpose: To investigate the risk factors for subconjunctival hemorrhage (SCH) after intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) and evaluate the relationship between hemodynamic status at the time of injection and SCH. Methods: We retrospectively reviewed the medical records of 598 cases of 173 patients who underwent intravitreal injection of ranibizumab whose hemodynamic status was monitored at the time of the injection. Cases with SCH after the injection were included in the SCH group. We compared systemic factors, including the hemodynamic status between the SCH group and the control group. Results: The SCH group included 67 cases and the control group included 531 cases without SCH. Baseline hemodynamic status was not significantly related to development of SCH. However, systolic blood pressure (BP) at injection was a significant risk factors for SCH (P = 0.034). Elevated systolic BP, mean arterial pressure (MAP), and pulse rate from baseline to time of injection were significantly related to the development of SCH (P = 0.011, P = 0.014, P = 0.036, respectively). In multivariate analysis, hypertension, a large change in MAP, and a fewer previous injections were significant risk factors for SCH after intravitreal injection (P = 0.030, P = 0.032, P = 0.028, respectively). Conclusions: Hemodynamic risk factors exist for SCH after intravitreal injection of anti-VEGF. To reduce the risk of SCH, strategies should seek to decrease patient anxiety, especially in those with hypertension.

AB - Purpose: To investigate the risk factors for subconjunctival hemorrhage (SCH) after intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) and evaluate the relationship between hemodynamic status at the time of injection and SCH. Methods: We retrospectively reviewed the medical records of 598 cases of 173 patients who underwent intravitreal injection of ranibizumab whose hemodynamic status was monitored at the time of the injection. Cases with SCH after the injection were included in the SCH group. We compared systemic factors, including the hemodynamic status between the SCH group and the control group. Results: The SCH group included 67 cases and the control group included 531 cases without SCH. Baseline hemodynamic status was not significantly related to development of SCH. However, systolic blood pressure (BP) at injection was a significant risk factors for SCH (P = 0.034). Elevated systolic BP, mean arterial pressure (MAP), and pulse rate from baseline to time of injection were significantly related to the development of SCH (P = 0.011, P = 0.014, P = 0.036, respectively). In multivariate analysis, hypertension, a large change in MAP, and a fewer previous injections were significant risk factors for SCH after intravitreal injection (P = 0.030, P = 0.032, P = 0.028, respectively). Conclusions: Hemodynamic risk factors exist for SCH after intravitreal injection of anti-VEGF. To reduce the risk of SCH, strategies should seek to decrease patient anxiety, especially in those with hypertension.

KW - Anti-vascular endothelial growth factor

KW - hemodynamic risk factors

KW - Intravitreal injection

KW - Subconjunctival hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=84940439246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940439246&partnerID=8YFLogxK

U2 - 10.1007/s00417-014-2837-6

DO - 10.1007/s00417-014-2837-6

M3 - Article

C2 - 25408422

AN - SCOPUS:84940439246

VL - 253

SP - 1465

EP - 1470

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 9

ER -